Panel Components:
CD9, CD19, CD34, CD38, CD45, CD90, CD117, CD133, HLA-DR

Methodology: FLOW

Clinical Significance:
This tube is added whenever >20% myeloid blasts are identified by flow cytometry (often when >10% blasts are identified), in order to provide additional characterization of the blasts. This tube can also be helpful in distinguishing benign regenerating myeloid blasts from leukemic myeloid blasts in the setting of post therapy bone marrows. This tube includes antibodies to CD45, CD9, CD133, CD34, CD90, HLA-DR, CD117, CD19, and CD38. Because of recent reports suggesting the prognostic significance of CD25 in AML, we are considering swapping the CD25 for the CD90.

Organ: Blood/Bone Marrow

Disease State: Acute Myeloid Leukemia (AML) / Myeloid Sarcoma

CPT Code(s): 88185x9 (reference only; CPTs may vary)

Turnaround Time: Physician will be contacted by 9:00 PM PST the day of receipt for acute/life threatening conditions; next business day for routine flow cases.

Schedule: Monday-Saturday

Specimen Requirements:
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Tissue: Finely minced tissue in RPMI transport media - OR -
• Body fluids: In RPMI transport media